Evidence map›Paper›PMID 38932292›Full record

ArticleVaccines2024

Enhancing

Hongxia Guo, Xiaoyan Ding, Dong Hua, Minchi Liu, Maocheng Yang, Yuanxin Gong, Nan Ye, Xiaozhong Chen, Jiuxiang He, Yu Zhang and 2 more

Abstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Impact of CeOGels (Basel, Switzerland) · 2025
    Article
  4. Article
  5. Cells · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hongxia GuoDepartment of Biosafety, School of Basic Medicine, Army Medical University, Chongqing 400038, China.
Xiaoyan DingDepartment of Biosafety, School of Basic Medicine, Army Medical University, Chongqing 400038, China.ORCID 0000-0003-0484-2750
Dong HuaDepartment of Biosafety, School of Basic Medicine, Army Medical University, Chongqing 400038, China.
Minchi LiuDepartment of Biosafety, School of Basic Medicine, Army Medical University, Chongqing 400038, China.
Maocheng YangDepartment of Biosafety, School of Basic Medicine, Army Medical University, Chongqing 400038, China.
Yuanxin GongDepartment of Biosafety, School of Basic Medicine, Army Medical University, Chongqing 400038, China.
Nan YeDepartment of Biosafety, School of Basic Medicine, Army Medical University, Chongqing 400038, China.
Xiaozhong ChenDepartment of Biosafety, School of Basic Medicine, Army Medical University, Chongqing 400038, China.
Jiuxiang HeDepartment of Biosafety, School of Basic Medicine, Army Medical University, Chongqing 400038, China.
Yu ZhangDepartment of Biosafety, School of Basic Medicine, Army Medical University, Chongqing 400038, China.ORCID 0000-0002-5898-9769
Xiaofeng XuDepartment of Biosafety, School of Basic Medicine, Army Medical University, Chongqing 400038, China.ORCID 0009-0002-1650-2737
Jintao LiDepartment of Biosafety, School of Basic Medicine, Army Medical University, Chongqing 400038, China.

Funding

Jintao Li 81570497
6 · The paper itself

Abstract

The dengue virus, the primary cause of dengue fever, dengue hemorrhagic fever, and dengue shock syndrome, is the most widespread mosquito-borne virus worldwide. In recent decades, the prevalence of dengue fever has increased markedly, presenting substantial public health challenges. Consequently, the development of an efficacious vaccine against dengue remains a critical goal for mitigating its spread. Our research utilized Celcradle™, an innovative tidal bioreactor optimized for high-density cell cultures, to grow Vero cells for dengue virus production. By maintaining optimal pH levels (7.0 to 7.4) and glucose concentrations (1.5 g/L to 3.5 g/L) during the proliferation of cells and viruses, we achieved a peak Vero cell count of approximately 2.46 × 10

Indexed as

bioreactordengue virusimmunogenicityvaccine

Identifiers

PMID38932292
PMCPMC11209354

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.